Corient Private Wealth LLC Acquires 57,055 Shares of Intuitive Surgical, Inc. $ISRG

Corient Private Wealth LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 17.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 378,838 shares of the medical equipment provider’s stock after purchasing an additional 57,055 shares during the quarter. Corient Private Wealth LLC’s holdings in Intuitive Surgical were worth $214,891,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new stake in Intuitive Surgical during the 4th quarter worth about $2,856,987,000. J. Stern & Co. LLP grew its holdings in shares of Intuitive Surgical by 18,504.6% in the 4th quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock valued at $1,204,788,000 after acquiring an additional 2,115,814 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Intuitive Surgical by 1,043.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock valued at $760,124,000 after acquiring an additional 1,224,734 shares in the last quarter. Polen Capital Management LLC bought a new position in shares of Intuitive Surgical in the 4th quarter valued at about $477,225,000. Finally, Assenagon Asset Management S.A. increased its position in shares of Intuitive Surgical by 106.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,533,771 shares of the medical equipment provider’s stock valued at $868,667,000 after acquiring an additional 791,516 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on ISRG shares. JPMorgan Chase & Co. dropped their target price on Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. TD Cowen decreased their price target on Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. HSBC lowered their price target on Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. The Goldman Sachs Group set a $558.00 price objective on Intuitive Surgical in a report on Wednesday, May 27th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating for the company in a research note on Tuesday, June 2nd. Nineteen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $573.42.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $406.78 on Friday. Intuitive Surgical, Inc. has a 52-week low of $396.68 and a 52-week high of $603.88. The company has a market capitalization of $144.07 billion, a P/E ratio of 49.31, a price-to-earnings-growth ratio of 3.31 and a beta of 1.46. The company has a 50-day simple moving average of $438.43 and a 200 day simple moving average of $490.46.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping the consensus estimate of $2.08 by $0.42. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.81 EPS. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Gary Loeb sold 400 shares of the stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total value of $169,656.00. Following the transaction, the executive vice president directly owned 5,720 shares of the company’s stock, valued at $2,426,080.80. This represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $463.50, for a total transaction of $55,156.50. Following the sale, the director owned 120 shares of the company’s stock, valued at approximately $55,620. This represents a 49.79% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,169 shares of company stock valued at $3,059,135 in the last quarter. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.